NCT00193050View on ClinicalTrials.gov

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2009

Conditions

Breast Cancer

Interventions

DRUG

Gemcitabine

Gemcitabine

DRUG

Epirubicin

Epirubicin

DRUG

Docetaxel

Docetaxel

Sponsors

Collaborators (1)

Aventis Pharmaceuticals

All Listed Sponsors

collaborator

Pharmacia and Upjohn

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER